Literature DB >> 13372956

The intracellular activation of pyrazinamide and nicotinamide.

G B MACKANESS.   

Abstract

Entities:  

Keywords:  MYCOBACTERIUM TUBERCULOSIS/effect of drugs on; NICOTINIC ACID/related compounds

Mesh：

Substances：

Year:  1956        PMID： 13372956     DOI： 10.1164/artpd.1956.74.5.718

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  20 in total

1.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

2.  Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.

Authors:  Claire M Naftalin; Rupangi Verma; Meera Gurumurthy; Qingshu Lu; Matthew Zimmerman; Benjamin Chaik Meng Yeo; Kin Hup Tan; Wenwei Lin; Buduo Yu; Véronique Dartois; Nicholas I Paton
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Authors:  Helena I Boshoff; Valerie Mizrahi; Clifton E Barry
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

4.  Current concepts in the treatment of tuberculosis.

Authors:  I B Tager
Journal:  West J Med       Date:  1987-04

5.  Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis.

Authors:  N Rastogi; M C Potar; H L David
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

6.  Host-parasite interactions with peritoneal macrophages of mice and rats in vitro and in vivo.

Authors:  W H Wagner
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

7.  Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.

Authors:  G P Morlock; J T Crawford; W R Butler; S E Brim; D Sikes; G H Mazurek; C L Woodley; R C Cooksey
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Authors:  A Scorpio; P Lindholm-Levy; L Heifets; R Gilman; S Siddiqi; M Cynamon; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

9.  Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.

Authors:  S P Klemens; C A Sharpe; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

10.  Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.

Authors:  R J Speirs; J T Welch; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.